GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (BSP:N1VO34) » Definitions » Cyclically Adjusted PB Ratio

Novo Nordisk A/S (BSP:N1VO34) Cyclically Adjusted PB Ratio : 71.21 (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted PB Ratio?

As of today (2024-04-30), Novo Nordisk A/S's current share price is R$81.89. Novo Nordisk A/S's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was R$1.15. Novo Nordisk A/S's Cyclically Adjusted PB Ratio for today is 71.21.

The historical rank and industry rank for Novo Nordisk A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:N1VO34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 15.64   Med: 24.75   Max: 70.32
Current: 68.73

During the past years, Novo Nordisk A/S's highest Cyclically Adjusted PB Ratio was 70.32. The lowest was 15.64. And the median was 24.75.

BSP:N1VO34's Cyclically Adjusted PB Ratio is ranked worse than
99.38% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs BSP:N1VO34: 68.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novo Nordisk A/S's adjusted book value per share data for the three months ended in Dec. 2023 was R$17.135. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$1.15 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted PB Ratio Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.05 24.49 37.79 40.65 54.23

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.65 45.47 45.19 51.19 54.23

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted PB Ratio falls into.



Novo Nordisk A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novo Nordisk A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=81.89/1.15
=71.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Novo Nordisk A/S's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=17.135/116.7000*116.7000
=17.135

Current CPI (Dec. 2023) = 116.7000.

Novo Nordisk A/S Quarterly Data

Book Value per Share CPI Adj_Book
201403 2.630 99.600 3.082
201406 2.717 99.700 3.180
201409 2.900 99.700 3.394
201412 3.328 99.400 3.907
201503 2.760 100.200 3.214
201506 3.455 100.300 4.020
201509 4.870 100.200 5.672
201512 5.115 99.800 5.981
201603 3.958 100.200 4.610
201606 4.234 100.600 4.912
201609 3.971 100.200 4.625
201612 4.221 100.300 4.911
201703 3.553 101.200 4.097
201706 4.914 101.200 5.667
201709 4.799 101.800 5.501
201712 5.220 101.300 6.014
201803 4.938 101.700 5.666
201806 5.995 102.300 6.839
201809 6.338 102.400 7.223
201812 6.265 102.100 7.161
201903 5.762 102.900 6.535
201906 6.522 102.900 7.397
201909 6.804 102.900 7.716
201912 7.325 102.900 8.307
202003 8.379 103.300 9.466
202006 10.086 103.200 11.405
202009 10.954 103.500 12.351
202012 11.335 103.400 12.793
202103 11.435 104.300 12.794
202106 11.637 105.000 12.934
202109 12.061 105.800 13.304
202112 13.158 106.600 14.405
202203 10.785 109.900 11.452
202206 11.787 113.600 12.109
202209 11.841 116.400 11.872
202212 13.857 115.900 13.953
202303 13.304 117.300 13.236
202306 14.257 116.400 14.294
202309 14.697 117.400 14.609
202312 17.135 116.700 17.135

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk A/S  (BSP:N1VO34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novo Nordisk A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (BSP:N1VO34) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (BSP:N1VO34) Headlines

No Headlines